Total views : 106

Genetic Perspective of Hepatocellular Carcinoma (HCC) in Asian population - A Review

Affiliations

  • Department of Genetic Engineering, SRM University, Kattankulathur – 603203, Tamil Nadu, India

Abstract


Hepatocellular Carcinoma (HCC) is the fifth most common cancer which causes thousands of death worldwide and the majority of the HCC sufferers are from Asia. Infection of Hepatitis B Virus and Hepatitis C Virus are major reasons for the development of HCC. The factors which add to its persistence are both environmental and genetic. Asia being a vast continent has a huge diversity of both. Polymorphisms in different genes linked with HCC lead to either increase or decrease in its risk. In this review we have focused on genetic factors responsible for HCC, with a special perspective based on the geography. According to the UN geo-scheme Asia is split into Eastern, Southeastern, Southern, Western and Central Asia. Here we have discussed on various genetic mutations which may or may not be the risk factor for HCC. The maximum HCC linked genetic mutations were observed in the Eastern region especially in China. *

Keywords

Asian Population, Genetic Factor, Hepatocellular Carcinoma, Polymorphisms, UN geo-scheme

Full Text:

 |  (PDF views: 84)

References


  • Stewart BW, Wild CP. World cancer report 2014. World.2015 Nov 13.
  • De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clinical Infectious Diseases. 2008 Jun 15; 46(12):1813–21. PMid:18462102, PMCid:PMC2671227.CrossRef.
  • Alwan A. Global status report on noncommunicable diseases 2010. World Health Organization; 2011.
  • Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes.Pharmaceutical Research. 2008 Sep 1; 25(9):2097–116.PMid:18626751, PMCid:PMC2515569. CrossRef.
  • Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER. AACR Cancer progress report 2013. Clinical Cancer Research. 2013 Oct 15; 19(20 Supplement):S1–98.PMid: 24045178. CrossRef.
  • Croce CM. Oncogenes and cancer. New England Journal of Medicine. 2008 Jan 31; 358(5):502–11. PMid: 18234754.CrossRef.
  • Knudson AG. Two genetic hits (more or less) to cancer. Nature Reviews Cancer. 2001 Nov 1; 1(2):157–62. PMid: 11905807. CrossRef.
  • Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR. Prevalence of BRCA1 and BRCA2 gene mutations in patients with earlyonset breast cancer. Journal of the National Cancer Institute.1999 Jun 2; 91(11):943–9. PMid: 10359546. CrossRef.
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer statistics. CA: A cancer journal for clinicians.2011 Mar 1; 61(2):69–90. PMid: 21296855. CrossRef.
  • Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003 Aug 11; 22(33):5093–107. PMid: 12910247. CrossRef.
  • Hu Q, Lou GG, Liu YC, Qian L, Lv BD. The tumor necrosis factor-α-308 and-238 polymorphisms and risk of Hepatocellular Carcinoma for Asian populations: a meta-analysis. Current Therapeutic Research. 2014 Dec 31; 76:70–5. PMid:25352937, PMCid:PMC4209508.CrossRef.
  • Guo XF, Wang J, Yu SJ, Song J, Ji MY, Cao Z, Zhang JX, Wang J, Dong WG. TNF-α-308 polymorphism and risk of digestive system cancers: a meta-analysis. World journal of gastroenterology: WJG. 2013 Dec 28;19(48):9461
  • Tian X, Ma P, Sui C, Li Y, Fu L, Jiang T, Wang Y, Jiang Y. Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk. Tumor Biology. 2014 Jan 1; 35(1):103–9.PMid: 23943369. CrossRef.
  • Ding C, Yu H, Qin H. Tp53 codon 72 polymorphism with hepatocellular carcinoma: a meta-analysis. Journal of International Medical Research. 2012 Apr 1; 40(2):446–54. PMid: 22613405. CrossRef.
  • Han SX, Wang L, Wu DQ. The association between UGT1A7 polymorphism and cancer risk: A meta-analysis.Cancer Epidemiology. 2012 Aug 31; 36(4):e201–6. PMid: 22402308. CrossRef.
  • He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z, Chen L, Song G, Gao T, Li R, Wang S. The association between four genetic variants in microRNAs (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: Evidence from published studies. PLoS One. 2012 Nov 14; 7(11):e49032. PMid: 23155448, PMCid: PMC3498348. CrossRef.
  • Xu Y, Gu L, Pan Y, Li R, Gao T, Song G, Nie Z, Chen L, Wang S, He B. Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: Evidence from published literatures. PLoS One. 2013 Jun 1; 8(6). CrossRef.
  • Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor α and risk of gastric cancer in a Chinese population. Carcinogenesis. 2005 Mar 1; 26(3):631–6. PMid: 15579481. CrossRef.
  • Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT, Yang JY. Interleukin-10 gene polymorphisms and Hepatocellular Carcinoma susceptibility:A meta-analysis. World J Gastroenterol. 2011 Sep 14; 17(34):3941–7. PMid: 22025883, PMCid: PMC3198024. CrossRef.
  • Saelee P, Wongkham S, Chariyalertsak S, Petmitr S, Chuensumran U. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac J Cancer Prev. 2010 Jan 1; 11(6):1677–81. PMid: 21338215.
  • Wu J, Zhang W, Xu A, Zhang L, Yan T, Li Z, Wu X, Zhu X, Ma J, Li K, Li H. Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related Hepatocellular Carcinoma in the population of North China. Genetic Testing and Molecular Biomarkers. 2013 Aug 1; 17(8):595–600. PMid: 23790025, PMCid: PMC3732435. CrossRef.
  • Yu Q, Zhou CX, Chen NS, Zheng SD, Shen LM, Zhang JK. A polymorphism within ErbB4 is associated with risk for Hepatocellular Carcinoma in Chinese population. World J Gastroenterol. 2012 Jan 28; 18(4):383–7. PMid: 22294845, PMCid: PMC3261534. CrossRef.
  • Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt MA, Li X.Correlation of LAPTM4B polymorphisms with Hepatocellular Carcinoma in Chinese patients. Medical Oncology. 2012 Dec 1; 29(4):2744–9. PMid: 22207410. CrossRef.
  • Qi F, Huang M, Pan Y, Liu Y, Liu J, Wen J, Xie K, Shen H, Ma H, Miao Y, Hu Z. A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related Hepatocellular Carcinoma in Chinese. PloS one. 2014 Jan 8; 9(1):e85394. PMid: 24416400, PMCid: PMC3885710. CrossRef.
  • Castelli EC, Moreau P, e Chiromatzo AO, Mendes-Junior CT, Veiga-Castelli LC, Yaghi L, Giuliatti S, Carosella ED, Donadi EA. In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes.Human Immunology. 2009 Dec 31; 70(12):1020–5. PMid: 19664672. CrossRef.
  • Yu L, Wang CY, Xi B, Sun L, Wang RQ, Yan YK, Zhu LY.GST polymorphisms are associated with Hepatocellular Carcinoma risk in Chinese population. World J Gastroenterol. 2011 Jul 21; 17(27):3248–56. PMid: 21912475, PMCid: PMC3158402.
  • Zhao J, Yu BY, Wang DY, Yang JE. Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. World J Gastroenterol. 2010 Dec 28; 16(48):6104– 10. PMid: 21182225, PMCid: PMC3012574. CrossRef.
  • Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1–related Hepatocellular Carcinoma in the Guangxi population. Hepatology. 2010 Oct 1; 52(4):1301–9. PMid: 20658464. CrossRef.
  • Kim H, Park CK, Lee SJ, Rha SY, Park KH, Lim HY. PIK3CA mutations in hepatocellular carcinoma in Korea. Yonsei medical journal. 2013 Jul 1;54(4):883–7.
  • Peng Q, Qin X, He Y, Chen Z, Deng Y, Li T, Xie L, Zhao J, Li S. Association of IL27 gene polymorphisms and HBV-related Hepatocellular Carcinoma risk in a Chinese population. Infection, Genetics and Evolution. 2013 Jun 30; 16:1–4. PMid: 23395794. CrossRef.
  • Jin Y, Yu Q, Zhou D, Chen L, Huang X, Xu G, Huang J, Gao X, Gao Y, Shen L. The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for Hepatocellular Carcinoma in the Chinese population. Genetic testing and molecular biomarkers. 2012 May 1; 16(5):330–4. PMid: 22283196, PMCid: PMC3354583. CrossRef.
  • Zhong R, Tian Y, Liu L, Qiu Q, Wang Y, Rui R, Yang BF, Duan SY, Shi JX, Miao XP, Wang L. HBV-related Hepatocellular Carcinoma susceptibility gene KIF1B is not associated with development of chronic hepatitis B. PLoS One. 2012 Feb 21; 7(2):e28839. PMid: 22363396, PMCid: PMC3283615.CrossRef.
  • Saxena R, Chawla YK, Verma I, Kaur J. IFN-γ (+ 874) and not TNF-α (− 308) is associated with HBV-HCC risk in India. Molecular and Cellular Biochemistry. 2014 Jan 1; 385(1-2):297–307. PMid: 24101445. CrossRef.
  • Kiran M, Chawla YK, Jain M, Kaur J. Haplotypes of microsomal epoxide hydrolase and X-ray cross-complementing group 1 genes in Indian Hepatocellular Carcinoma patients.DNA and Cell Biology. 2009 Nov 1; 28(11):573–7. PMid: 19754350. CrossRef. CrossRef.
  • Utama A, Siburian MD, Fanany I, Intan MD, Dhenni R, Kurniasih TS, Lelosutan SA, Achwan WA, Zubir N. Hepatitis B virus pre-S2 start codon mutations in Indonesian liver disease patients. World journal of gastroenterology: WJG. 2012 Oct 14;18(38):5418.
  • Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alphafetoprotein secretion during Hepatocellular Carcinoma progression and represents a potential target for therapeutic intervention. Journal of Hepatology. 2009 Jan 31; 50(1):118–27. PMid: 19008009. CrossRef.
  • Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y. Interleukin-1 beta gene polymorphism associated with Hepatocellular Carcinoma in Hepatitis B Virus infection. World Journal of Gastroenterology. 2006 Feb 7; 12(5):776. PMid: 16521194, PMCid: PMC4066131. CrossRef.
  • Akkiz H, Bayram S, Bekar A, Ozdil B, Akgollu E, Sumbul AT, Demiryurek H, Doran F. G-308A TNF-α polymorphism is associated with an increased risk of Hepatocellular Carcinoma in the Turkish population: Case-control study.Cancer Epidemiology. 2009 Oct 31; 33(3):261–4. PMid: 19683483. CrossRef.
  • Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B. Cyclin D1 G870A polymorphism is associated with an increased risk of Hepatocellular Carcinoma in the Turkish population: Case–control study. Cancer Epidemiology. 2010 Jun 30; 34(3):298–302. PMid: 20347627. CrossRef.
  • Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E. MDM2 promoter polymorphism is associated with increased susceptibility to Hepatocellular Carcinoma in Turkish population.Cancer Epidemiology. 2010 Aug 31; 34(4):448–52.PMid: 20447891. CrossRef.
  • Bayram S, Akkiz H, Bekar A, Akgollu E, Yildırim S. The significance of exonuclease 1 K589E polymorphism on Hepatocellular Carcinoma susceptibility in the Turkish population: a case–control study. Molecular Biology Reports. 2012 May 1; 39(5):5943–51. PMid: 22205538.CrossRef.
  • Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y. A functional polymorphism in pre‐microRNA‐196a‐2 contributes to the susceptibility of Hepatocellular Carcinoma in a Turkish population: A case–control study. Journal of Viral Hepatitis. 2011 Jul 1; 18(7):e399–407. PMid: 21692953.CrossRef.
  • Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. p53 codon 72 polymorphism is associated with susceptibility to Hepatocellular Carcinoma in the Turkish population: A case–control study. Molecular Biology Reports. 2012 Feb 1; 39(2):1639–47. PMid: 21607615.CrossRef.
  • Akkız H, Bayram S, Bekar A, Akgollu E, Ozdil B. Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. Journal of Viral Hepatitis. 2010 Sep 1; 17(9):668–74. PMid: 20002563.
  • Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y, Kaya BY, Sandikci M, Ozdil B. No association of NAD (P) H: Quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of Hepatocellular Carcinoma development in Turkish subjects.Asian Pac J Cancer Prev. 2010 Jan 1; 11(4):1051–8.PMid: 21133623.
  • Park CH, Jeong SH, Yim HW, Kim JD, Bae SH, Choi JY, Yoon SK. Family history influences the early onset of hepatocellular carcinoma. World J Gastroenterol. 2012 Jun 7; 18(21):2661–7. PMid: 22690075, PMCid: PMC3370003.CrossRef.
  • Jiang JH, Gao Q, Shen XZ, Yu Y, Gu FM, Yan J, Pan JF, Jin F, Fan J, Zhou J, Huang XW. An X-chromosomal association study identifies a susceptibility locus at Xq22. 1 for Hepatitis B virus-related hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology. 2013 Dec 31; 37(6):586–95. PMid: 24209690. CrossRef.

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.